| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.96 [0.87, 1.07] | | < 1 | | 0% | 3 studies (3/-) | 75.9 % | low | not evaluable | high | crucial | - |
| progression or deaths (PFS) | 1.35 [0.99, 1.86] | | < 1 | | 88% | 3 studies (3/-) | 3.0 % | low | not evaluable | high | important | - |
| CBR | 1.01 [0.65, 1.55] | | > 1 | | 0% | 1 study (1/-) | 51.2 % | NA | not evaluable | | non important | - |
| DCR | 0.49 [0.36, 0.68] | | > 1 | | 25% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
| DOR | 0.95 [0.63, 1.43] | | < 1 | | 0% | 1 study (1/-) | 59.7 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 0.94 [0.70, 1.24] | | > 1 | | 0% | 3 studies (3/-) | 32.5 % | low | not evaluable | high | non important | - |
safety endpoints 00 |
| AE (grade 3-4) | 0.80 [0.56, 1.13] | | < 1 | | 0% | 1 study (1/-) | 89.9 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 2.02 [0.37, 11.12] | | < 1 | | 0% | 1 study (1/-) | 21.0 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (any grade) | 1.45 [0.89, 2.36] | | < 1 | | 0% | 1 study (1/-) | 6.9 % | NA | not evaluable | | non important | - |
| SAE (any grade) | 1.11 [0.83, 1.47] | | < 1 | | 0% | 2 studies (2/-) | 24.0 % | low | not evaluable | high | non important | - |
| STRAE (any grade) | 1.10 [0.68, 1.77] | | < 1 | | 0% | 1 study (1/-) | 35.1 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 0.51 [0.17, 1.52] | | < 1 | | 94% | 2 studies (2/-) | 88.6 % | low | not evaluable | high | non important | - |
| TRAE leading to death (grade 5) | 0.87 [0.36, 2.08] | | < 1 | | 0% | 2 studies (2/-) | 62.5 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 1.05 [0.42, 2.63] | | < 1 | | 0% | 1 study (1/-) | 45.7 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.94 [0.06, 15.18] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
| Acute kidney injury TRAE (grade 3-4) | 0.47 [0.02, 14.11] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Alopecia TRAE (grade 3-4) | 0.94 [0.02, 47.78] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 0.28 [0.08, 1.01] | | < 1 | | 0% | 1 study (1/-) | 97.3 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 1.26 [0.28, 5.69] | | < 1 | | 0% | 1 study (1/-) | 38.1 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 0.47 [0.02, 14.11] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
| Constipation TRAE (grade 3-4) | 0.47 [0.02, 14.11] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
| Cough TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.47 [0.02, 14.11] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
| Diabetes TRAE (grade 3-4) | 0.94 [0.06, 15.18] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.23 [0.05, 1.10] | | < 1 | | 0% | 1 study (1/-) | 96.7 % | NA | not evaluable | | non important | - |
| Dyspnoea TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 0.94 [0.19, 4.72] | | < 1 | | 0% | 1 study (1/-) | 52.8 % | NA | not evaluable | | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 0.05 [0.00, 0.79] | | < 1 | | 0% | 1 study (1/-) | 98.2 % | NA | not evaluable | | non important | - |
| Headache TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.94 [0.02, 47.78] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Increase AST TRAE (grade 3-4) | 1.91 [0.57, 6.42] | | < 1 | | 0% | 1 study (1/-) | 14.7 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 1.90 [0.17, 21.02] | | < 1 | | 0% | 1 study (1/-) | 30.3 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.09 [0.01, 1.71] | | < 1 | | 0% | 1 study (1/-) | 94.3 % | NA | not evaluable | | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Myalgia TRAE (grade 3-4) | 0.47 [0.02, 14.11] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
| Myositis TRAE (grade 3-4) | 5.72 [0.29, 114.60] | | < 1 | | 0% | 1 study (1/-) | 13.0 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.47 [0.02, 14.11] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
| Nephritis TRAE (grade 3-4) | 0.94 [0.02, 47.78] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.01 [0.00, 0.12] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.13 [0.02, 1.08] | | < 1 | | 0% | 1 study (1/-) | 97.0 % | NA | not evaluable | | non important | - |
| Pancytopenia TRAE (grade 3-4) | 0.24 [0.01, 5.23] | | < 1 | | 0% | 1 study (1/-) | 81.7 % | NA | not evaluable | | non important | - |
| Peripheral sensory neuropathy TRAE (grade 3-4) | 0.16 [0.01, 3.13] | | < 1 | | 0% | 1 study (1/-) | 88.5 % | NA | not evaluable | | non important | - |
| Pneumonia TRAE (grade 3-4) | 0.24 [0.01, 5.23] | | < 1 | | 0% | 1 study (1/-) | 81.7 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 5.72 [0.29, 114.60] | | < 1 | | 0% | 1 study (1/-) | 13.0 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.94 [0.06, 15.18] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
| Sepsis TRAE (grade 3-4) | 0.94 [0.02, 47.78] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 1.90 [0.17, 21.02] | | < 1 | | 0% | 1 study (1/-) | 30.3 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.47 [0.02, 14.11] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.94 [0.06, 15.18] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
| Thyroiditis TRAE (grade 3-4) | 0.94 [0.02, 47.78] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
| Urticaria TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Weight decreased TRAE (grade 3-4) | 0.47 [0.04, 5.22] | | < 1 | | 0% | 1 study (1/-) | 72.9 % | NA | not evaluable | | non important | - |
